ibudilast has been researched along with Disease Models, Animal in 24 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " VPA-exposed male pups were administered with two doses of ibudilast (5 and10 mg/kg) and all the groups were evaluated for behavioral parameters like social interaction, spatial memory/learning, anxiety, locomotor activity, and nociceptive threshold." | 8.31 | Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder. ( Gautam, V; Kumar, A; Rawat, K; Saha, L; Sandhu, A; Sharma, A, 2023) |
| " In this study, we examined the ability of ibudilast, a non-selective phosphodiesterase inhibitor, to reduce alcohol drinking and relapse in alcohol-preferring P rats, high-alcohol drinking HAD1 rats, and in mice made dependent on alcohol through cycles of alcohol vapor exposure." | 7.81 | Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. ( Becker, HC; Bell, RL; Cui, C; Egli, M; Franklin, KM; Johnson, KW; Lopez, MF, 2015) |
| "Ibudilast is a multi-target drug, as it is a phosphodiesterase inhibitor and toll-like receptor 4 (TLR4) antagonist." | 5.91 | Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation. ( Chaudry, O; Figueiredo-Pereira, ME; Liu, Q; Oliveros, G; Qiu, Y; Rockwell, P; Serrano, PA; Wallace, CH; Xie, L, 2023) |
| "Ibudilast is a phosphodiesterase inhibitor, effective on the function of glial cells and lymphocytes, and inhibits the release of TNF-α by inflammatory cells." | 5.91 | Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model. ( Aliomrani, M; Kazemi, M; Sharifian, A; Varshosaz, J, 2023) |
| "Glaucoma is a neurodegenerative disease and the leading cause of irreversible blindness worldwide." | 5.43 | The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling. ( Belforte, N; Cueva Vargas, JL; Di Polo, A, 2016) |
| " The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens." | 5.40 | Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. ( Ellis, A; Falci, S; Favret, J; Johnson, KW; Maier, SF; Rice, KC; Watkins, LR; Wieseler, J, 2014) |
| " VPA-exposed male pups were administered with two doses of ibudilast (5 and10 mg/kg) and all the groups were evaluated for behavioral parameters like social interaction, spatial memory/learning, anxiety, locomotor activity, and nociceptive threshold." | 4.31 | Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder. ( Gautam, V; Kumar, A; Rawat, K; Saha, L; Sandhu, A; Sharma, A, 2023) |
| " In this study, we examined the ability of ibudilast, a non-selective phosphodiesterase inhibitor, to reduce alcohol drinking and relapse in alcohol-preferring P rats, high-alcohol drinking HAD1 rats, and in mice made dependent on alcohol through cycles of alcohol vapor exposure." | 3.81 | Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. ( Becker, HC; Bell, RL; Cui, C; Egli, M; Franklin, KM; Johnson, KW; Lopez, MF, 2015) |
| "Krabbe disease (globoid cell leukodystrophy, GLD) is an inherited disease caused by a deficiency in the lysosomal enzyme galactocerebrosidase (GALC)." | 2.53 | Insights into the Pathogenesis and Treatment of Krabbe Disease. ( Bongarzone, ER; Escolar, ML; Gray, SJ; Kafri, T; Sands, MS; Vite, CH, 2016) |
| "Ibudilast (AV-411) is a non-selective phosphodiesterase inhibitor that is also known to suppress glial cell activation." | 2.44 | Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. ( Hutchinson, MR; Johnson, KW; Ledeboer, A; Watkins, LR, 2007) |
| "Ibudilast is a multi-target drug, as it is a phosphodiesterase inhibitor and toll-like receptor 4 (TLR4) antagonist." | 1.91 | Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation. ( Chaudry, O; Figueiredo-Pereira, ME; Liu, Q; Oliveros, G; Qiu, Y; Rockwell, P; Serrano, PA; Wallace, CH; Xie, L, 2023) |
| "Ibudilast is a phosphodiesterase inhibitor, effective on the function of glial cells and lymphocytes, and inhibits the release of TNF-α by inflammatory cells." | 1.91 | Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model. ( Aliomrani, M; Kazemi, M; Sharifian, A; Varshosaz, J, 2023) |
| "Roflumilast treatment (1nM delivered 6h post-injury) significantly increased total AMPA glutamate receptor 1 (GluR1) subunit expression, phosphorylation of the GluR1 subunit at the serine-831 site, and phosphorylation of stargazin at the serine-239/240 site upon LTP induction, measured 24h following injury." | 1.46 | Phosphodiesterase-4 inhibition restored hippocampal long term potentiation after primary blast. ( Bass, CR; Meaney, DF; Morales, FN; Morrison, B; Vogel, EW, 2017) |
| "Glaucoma is a neurodegenerative disease and the leading cause of irreversible blindness worldwide." | 1.43 | The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling. ( Belforte, N; Cueva Vargas, JL; Di Polo, A, 2016) |
| " In this study, we evaluated whether, in female rats, chronic administration of increasing doses of the psychotropic plant-derived cannabis constituent, delta-9-tetrahydrocannabinol (THC), during adolescence (PND 35-45) could affect microglia function in the long-term." | 1.42 | Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats. ( Gabaglio, M; Parolaro, D; Prini, P; Rubino, T; Zamberletti, E, 2015) |
| " The molecular mechanisms of unwanted opioid responses are varied but recent advances have highlighted elevations in pro-inflammatory cytokines and pro-inflammatory glial following chronic administration of morphine." | 1.40 | Role of phosphodiesterase inhibitor Ibudilast in morphine-induced hippocampal injury. ( Ahmadi Angali, K; Ghafurian Broujerdnia, M; Ghorbani, R; Panahi, M; Saki, G; Zhaleh, M, 2014) |
| " The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens." | 1.40 | Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. ( Ellis, A; Falci, S; Favret, J; Johnson, KW; Maier, SF; Rice, KC; Watkins, LR; Wieseler, J, 2014) |
| "Treatment with ibudilast down-regulated these molecules, suppressed macrophage migration into the aneurysm wall, and inhibited PDE-4 activation and the elevation of cyclic adenosine monophosphate in endothelial cells." | 1.36 | Ibudilast inhibits cerebral aneurysms by down-regulating inflammation-related molecules in the vascular wall of rats. ( Kitazato, KT; Nagahiro, S; Satomi, J; Tada, Y; Tamura, T; Yagi, K, 2010) |
| "However, their effects on thrombus formation have rarely been evaluated in experimental animals in vivo." | 1.29 | In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. ( Iwamoto, Y; Naritomi, H; Nishimura, H; Sugita, M; Tachibana, H, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 1 (4.17) | 29.6817 |
| 2010's | 14 (58.33) | 24.3611 |
| 2020's | 7 (29.17) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Oliveros, G | 1 |
| Wallace, CH | 1 |
| Chaudry, O | 1 |
| Liu, Q | 1 |
| Qiu, Y | 1 |
| Xie, L | 1 |
| Rockwell, P | 1 |
| Figueiredo-Pereira, ME | 1 |
| Serrano, PA | 1 |
| Sharifian, A | 1 |
| Varshosaz, J | 1 |
| Aliomrani, M | 1 |
| Kazemi, M | 1 |
| Sandhu, A | 1 |
| Rawat, K | 1 |
| Gautam, V | 1 |
| Sharma, A | 1 |
| Kumar, A | 1 |
| Saha, L | 1 |
| Yang, D | 1 |
| Yang, Y | 1 |
| Zhao, Y | 1 |
| Nguyen, LD | 1 |
| Fischer, TT | 1 |
| Abreu, D | 1 |
| Arroyo, A | 1 |
| Urano, F | 1 |
| Ehrlich, BE | 1 |
| Chang, Y | 1 |
| Hu, CC | 1 |
| Wu, YY | 1 |
| Ueng, SWN | 1 |
| Chang, CH | 1 |
| Chen, MF | 1 |
| Vogel, EW | 1 |
| Morales, FN | 1 |
| Meaney, DF | 1 |
| Bass, CR | 1 |
| Morrison, B | 1 |
| Schwenkgrub, J | 1 |
| Zaremba, M | 1 |
| Joniec-Maciejak, I | 1 |
| Cudna, A | 1 |
| Mirowska-Guzel, D | 1 |
| Kurkowska-Jastrzębska, I | 1 |
| Rodgers, KM | 1 |
| Deming, YK | 1 |
| Bercum, FM | 1 |
| Chumachenko, SY | 1 |
| Wieseler, JL | 1 |
| Johnson, KW | 4 |
| Watkins, LR | 3 |
| Barth, DS | 1 |
| Zhaleh, M | 1 |
| Panahi, M | 1 |
| Ghafurian Broujerdnia, M | 1 |
| Ghorbani, R | 1 |
| Ahmadi Angali, K | 1 |
| Saki, G | 1 |
| Bell, RL | 1 |
| Lopez, MF | 1 |
| Cui, C | 1 |
| Egli, M | 1 |
| Franklin, KM | 1 |
| Becker, HC | 1 |
| Ellis, A | 1 |
| Wieseler, J | 1 |
| Favret, J | 1 |
| Rice, KC | 1 |
| Maier, SF | 1 |
| Falci, S | 1 |
| Coiro, P | 1 |
| Padmashri, R | 1 |
| Suresh, A | 1 |
| Spartz, E | 1 |
| Pendyala, G | 1 |
| Chou, S | 1 |
| Jung, Y | 1 |
| Meays, B | 1 |
| Roy, S | 1 |
| Gautam, N | 1 |
| Alnouti, Y | 1 |
| Li, M | 1 |
| Dunaevsky, A | 1 |
| Zamberletti, E | 1 |
| Gabaglio, M | 1 |
| Prini, P | 1 |
| Rubino, T | 1 |
| Parolaro, D | 1 |
| Cueva Vargas, JL | 1 |
| Belforte, N | 1 |
| Di Polo, A | 1 |
| Bongarzone, ER | 1 |
| Escolar, ML | 1 |
| Gray, SJ | 1 |
| Kafri, T | 1 |
| Vite, CH | 1 |
| Sands, MS | 1 |
| Yagi, K | 1 |
| Tada, Y | 1 |
| Kitazato, KT | 1 |
| Tamura, T | 1 |
| Satomi, J | 1 |
| Nagahiro, S | 1 |
| Lee, JY | 1 |
| Cho, E | 1 |
| Ko, YE | 1 |
| Kim, I | 1 |
| Lee, KJ | 1 |
| Kwon, SU | 1 |
| Kang, DW | 1 |
| Kim, JS | 1 |
| Schwarz, JM | 1 |
| Bilbo, SD | 1 |
| Ledeboer, A | 1 |
| Hutchinson, MR | 1 |
| Nishimura, H | 1 |
| Naritomi, H | 1 |
| Iwamoto, Y | 1 |
| Tachibana, H | 1 |
| Sugita, M | 1 |
| Fujimoto, T | 1 |
| Sakoda, S | 1 |
| Fujimura, H | 1 |
| Yanagihara, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Full-Factorial, Parallel-Group Study Evaluating Safety and Efficacy of Naltrexone-Acetaminophen Combination in Acute Migraine Treatment in Adults, With Exploratory Focus on Co-Occurring[NCT05685225] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| Uncovering Inflammatory Mediators of Glaucoma Pathogenesis After Corneal Transplantation in Aqueous Humor and Tears[NCT04339907] | 200 participants (Anticipated) | Interventional | 2020-05-11 | Recruiting | |||
| A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-05-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ibudilast and Disease Models, Animal
| Article | Year |
|---|---|
Insights into the Pathogenesis and Treatment of Krabbe Disease.
Topics: Acetylcysteine; Animals; Antimetabolites; Bone Marrow Transplantation; Central Nervous System; Cyclo | 2016 |
Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 2007 |
22 other studies available for ibudilast and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Drug Repositioning; Femal | 2023 |
Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model.
Topics: Animals; Brain; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Mice; Mice, Inb | 2023 |
Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder.
Topics: Animals; Anxiety; Autism Spectrum Disorder; Disease Models, Animal; Female; Inflammation Mediators; | 2023 |
Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Acute Respiratory Distress Syndrome in Neonatal Mice by Alleviating Inflammation and Apoptosis.
Topics: Animals; Animals, Newborn; Apoptosis; Bronchoalveolar Lavage Fluid; Cyclic Nucleotide Phosphodiester | 2020 |
Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome.
Topics: Animals; Antineoplastic Agents; Calcium; Calmodulin-Binding Proteins; Cell Survival; Cysteine Protei | 2020 |
Ibudilast Mitigates Delayed Bone Healing Caused by Lipopolysaccharide by Altering Osteoblast and Osteoclast Activity.
Topics: Animals; Biomarkers; Bone and Bones; Cell Line; Disease Models, Animal; Immunohistochemistry; Lipopo | 2021 |
Phosphodiesterase-4 inhibition restored hippocampal long term potentiation after primary blast.
Topics: Aminopyridines; Animals; Animals, Newborn; Benzamides; Blast Injuries; Cell Death; Cyclic Nucleotide | 2017 |
The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.
Topics: Animals; Astrocytes; Disease Models, Animal; Glial Cell Line-Derived Neurotrophic Factor; Interleuki | 2017 |
Reversal of established traumatic brain injury-induced, anxiety-like behavior in rats after delayed, post-injury neuroimmune suppression.
Topics: Animals; Anxiety; Behavior, Animal; Brain Injuries; Disease Models, Animal; Freezing Reaction, Catal | 2014 |
Role of phosphodiesterase inhibitor Ibudilast in morphine-induced hippocampal injury.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Hippocampus; Interleukin-1beta; M | 2014 |
Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Male; Mice; Phospho | 2015 |
Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.
Topics: Animals; Disease Models, Animal; Hyperalgesia; Male; Naltrexone; Narcotic Antagonists; Neuralgia; Ne | 2014 |
Impaired synaptic development in a maternal immune activation mouse model of neurodevelopmental disorders.
Topics: Animals; Anti-Inflammatory Agents; Dendritic Spines; Disease Models, Animal; Excitatory Postsynaptic | 2015 |
Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats.
Topics: Age Factors; Animals; Animals, Newborn; Cognition Disorders; Cyclooxygenase 2; Cytokines; Disease Mo | 2015 |
The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling.
Topics: Animals; Axonal Transport; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Disease Models, Anim | 2016 |
Ibudilast inhibits cerebral aneurysms by down-regulating inflammation-related molecules in the vascular wall of rats.
Topics: Angiotensin II; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Line, Transfo | 2010 |
Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory activity, protects against ischemic brain injury in rats.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Brain Edema; Brain Infarction; Cell Death; Cytokines; | 2012 |
Adolescent morphine exposure affects long-term microglial function and later-life relapse liability in a model of addiction.
Topics: Age Factors; Animals; Conditioning, Operant; Disease Models, Animal; Drug-Seeking Behavior; Microgli | 2013 |
In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis.
Topics: Animals; Aspirin; Carotid Artery Diseases; Carotid Artery Injuries; Carotid Artery, Common; Cerebrov | 1996 |
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Topics: Administration, Oral; Animals; Cell Division; Disease Models, Animal; Encephalomyelitis, Autoimmune, | 1999 |